Ignite Creation Date:
2025-12-25 @ 2:24 AM
Ignite Modification Date:
2026-02-28 @ 10:35 PM
Study NCT ID:
NCT03221634
Status:
WITHDRAWN
Last Update Posted:
2019-03-25
First Post:
2017-07-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-08-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2019-03-20
Primary Completion Date Type:
ESTIMATED
Completion Date:
2021-06-10
Completion Date Type:
ESTIMATED
First Submit Date:
2017-07-17
First Submit QC Date:
None
Study First Post Date:
2017-07-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-03-21
Last Update Post Date:
2019-03-25
Last Update Post Date Type:
ACTUAL